Review Article
Volume 8 Issue 8 - 2020
Management of SARS-COV-2; The Missing Link?: A Critical Pharmaco-Immuno-Logical Review
Hussain Mookhtiar1*, Vivek Hegde2, Mariya Murtuza Shamsi3, Khatija Memon1 and Meheriar A Chopra4
1PG Student, Department of Conservative Dentistry and Endodontics, M.A. Rangoonwala Dental College and Research Centre, Pune, India
2Professor and HOD, Department of Conservative Dentistry and Endodontics, M.A. Rangoonwala Dental College and Research Centre, Pune, India
3Under-graduate Student, Baroda Medical College, Vadodara, Gujarat, India
4Senior Lecturer, Department of Conservative Dentistry and Endodontics, M.A. Rangoonwala Dental College and Research Centre, Pune, India
*Corresponding Author: Hussain Mookhtiar, PG Student, Department of Conservative Dentistry and Endodontics, M.A. Rangoonwala Dental College and Research Centre, Pune, India.
Received: June 28, 2020; Published: July 17, 2020


The pandemic of SARS-CoV-2 which started in Wuhan, China has now affected almost every corner of the world. The number of death tolls continues to rise and a large number of countries have been forced to do social distancing and lockdown. Lack of targeted therapy continues to be a problem Till date there have many treatment protocols followed on a trial and error basis. Many human trials on a definitive treatment of this virus is also taking place in different part of the world. SARS-CoV-2 has the ability to bind to human angiotensin-converting enzyme 2 receptors causing deleterious effects. The main aim of this review is to critically assess every pharmacological and its immunological effects in this SARS-CoV-2 pandemic.

Keywords: SARS-Cov-2; COVID-19; Pharmacological Management; Immunological Management


  1. Dong E., et al. “An interactive web-based dashboard to track COVID-19 in real time”. The Lancet Infectious Diseases (2020).
  2. Gorbalenya AE., et al. “The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2”. Nature Microbiology (2020).
  3. Wax RS and Christian MD. “Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients”. The Canadian Journal of Anesthesia (2020).
  4. Wahba L., et al. “Identification of a pangolin niche for a 2019-nCoV-like coronavirus through an extensive meta-metagenomic search”. Bio Rxiv (2020).
  5. Kirk-Bayley J., et al. “The Use of Povidone Iodine Nasal Spray and Mouthwash During the Current COVID-19 Pandemic May Protect Healthcare Workers and Reduce Cross Infection (2020). 
  6. Zhao W., et al. “Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study”. American Journal of Roentgenology 214.5 (2020): 1072-1077.
  7. Ather A., et al. “Coronavirus disease 19 (COVID-19): implications for clinical dental care”. Journal of Endodontics (2020). 
  8. Eggers M., et al. “Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses”. BMC Infectious Diseases 15.1 (2015): 375.
  9. Kariwa H., et al. “Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents”. Japanese Journal of Veterinary Research 52.3 (2004): 105-112.
  10. Mady LJ., et al. “Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as “Personal Protective Equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care”. Oral Oncology (2020): 16.
  11. Tipnis SR., et al. “A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase”. Journal of Biological Chemistry 275 (2000): 33238-33243.
  12. Daschbach JL., et al. “Molecular mechanisms of hydrogen-loaded β-hydroquinone clathrate”. The Journal of Physical Chemistry B 110.35 (2006): 17291-17295.
  13. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends (2020).
  14. Singh AK., et al. “Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2020).
  15. Gautret P., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. International Journal of Antimicrobial Agents (2020): 105949.
  16. Yao GU., et al. “Tris (8-hydroxyquinoline) aluminium nanostructure film and its fluorescence properties”. Chinese Physics Letters 25.12 (2008): 4428.
  17. Patrì A and Fabbrocini G. “Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?”. Journal of the American Academy of Dermatology 82.6 (2020): e221.
  18. Caly L., et al. “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro”. Antiviral Research (2020): 104787.
  19. Yavuz S and Ünal S. “Antiviral treatment of COVID-19”. Turkish Journal of Medical Science 1 (2020): 611-619.
  20. Choudhary R and Sharma AK. “Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance”. New Microbes and New Infections (2020): 100684.
  21. Momekov G and Momekova D. “Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens”. Med Rxiv (2020).
  22. "Ribavirin". The American Society of Health-System Pharmacists.
  23. Ortega-Prieto AM., et al. Vartanian J (edition.) (2013).
  24. Koren G., et al. “Ribavirin in the treatment of SARS: A new trick for an old drug?”. Canadian Medical Association Journal 168.10 (2003): 1289-1292.
  25. Yu WC., et al. “Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS).
  26. Ho JC., et al. “High–dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome”. American Journal of Respiratory and Critical Care Medicine 168.12 (2003): 1449-1456.
  27. Omrani AS., et al. “Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction”. Pathogens and Global Health 109.8 (2015): 354-362.
  28. Khalili JS., et al. “Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19”. Journal of Medical Virology 92.7 (2020): 740-746.
  29. Hung IF., et al. “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial”. The Lancet (2020).
  30. Du YX and Chen XP. "Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection". Clinical Pharmacology and Therapeutics (2020).
  31. Sissoko D., et al. “Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea”. PLoS Medicine 13.3 (2016).
  32. MK Jordan R Arvey A. “GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses”. Scientific Reports (2017): 743395.
  33. Gordon CJ., et al. “The antiviral compound Remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus”. Journal of Biological Chemistry 295.15 (2020): 4773-4779.
  34. Sheahan TP., et al. “Comparative therapeutic efficacy of Remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV”. Nature Communications 11.1 (2020): 1-4.
  35. Al-Tawfiq JA., et al. “Remdesivir as a possible therapeutic option for the COVID-19”. Travel Medicine and Infectious Disease (2020).
  36. Reina J. “Remdesivir, the antiviral hope against SARS-CoV-2. Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia (2020).
  37. Arturo Casadevall and Liise-anne Pirofski. “The convalescent sera option for containing COVID-19”. Journal of Clinical Investigation 130.4 (2020): 1545-1548.
  38. Cheng Y., et al. “Use of convalescent plasma therapy in SARS patients in Hong Kong”. European Journal of Clinical Microbiology and Infectious Diseases 24.1 (2005): 44-46.
  39. Zhang B., et al. “Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection”. Chest (2020): 30571-30577.
  40. Li G., et al. “Profile of specific antibodies to the SARS-associated coronavirus”. The New England Journal of Medicine 349.5 (2003): 508-509. 
  41. Syal K., et al. “COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy”. Journal of Medical Virology (2020).
  42. Zhou B., et al. “Treatment with convalescent plasma for influenza A (H5N1) infection”. The New England Journal of Medicine (2007).
  43. Li Q., et al. “Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia”. New England Journal of Medicine (2020).
  44. Sanche S., et al. “High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2”. Emerging Infectious Diseases 26 (2020).
  45. Randolph HE and Barreiro LB. “Herd Immunity: Understanding COVID-19”. Immunity 52.5 (2020): 737-741.
  46. Roper RL and Rehm KE. “SARS vaccines: where are we?” Expert Review of Vaccines 8.7 (2009): 887-898.
  47. Bolles M., et al. “A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge”. Journal of Virology 85.23 (2011): 12201-12215.
  48. Zhou Z., et al. “A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice”. Vaccine 24.17 (2006): 3624-3631.
  49. Amanat F and Krammer F. “SARS-CoV-2 vaccines: status report”. Immunity (2020).
Citation: Hussain Mookhtiar., et al. “Management of SARS-COV-2; The Missing Link?: A Critical Pharmaco-Immuno-Logical Review”. EC Pharmacology and Toxicology 8.8 (2020): 49-58.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for January Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the January issue of respective journals. Submissions are accepted on/before December 03, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to